If we like what we see tomorrow…
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
biopearl123
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
If we like what we see tomorrow…
Remember that Dr. Tefferi said in 2017 that he felt the depth of response in MF was significantly greater even than in MDS. If the data is strong there will almost certainly be more to come…. I am guessing trading will be suspended in AM.
Re: If we like what we see tomorrow…
So far this morning, Geron is fetching about 10,000 shares per minute to the upside.
Feels like a sick day at work. I'm a little feverish.
Feels like a sick day at work. I'm a little feverish.
Re: If we like what we see tomorrow…
Bp- Absolutely.....a better than expected readout should open the floodgates for all other indications targeted at this moment. I'm wondering if there was a reason why they downplayed the Lymphoma Pre-Clinical study?
"telomerase may be a therapeutic target for ABC-type DLBCL (diffuse large B-cell lymphoma); the novel telomerase inhibitor Imetelstat may present one of the potential treatment options."
https://ashpublications.org/blood/artic ... chresult=1
I know that "imetelstat single-agent activity on cell viability was limited in PTCL (peripheral T-cell lymphomas) cell lines"..... however, from a company/business perspective it makes sense to pursue type DLBCL even further.
"PTCL is classified as a subtype of non-Hodgkin’s lymphoma (NHL)."
https://lymphoma.org/understanding-lymp ... /nhl/ptcl/
PTCL - "is rare in the United States, accounting for less than 1.5 percent of all NHLs. Extranodal, nasal NK/T-cell lymphoma is more commonly found in Asia and Latin America and is associated with the Epstein-Barr virus (EBV)."
https://www.google.com/url?sa=t&source= ... jOy6ZRsanh
"Although there are more than 60 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas. In the United States, DLBCL affects about 7 out of 100,000 people each year. DLBCL is a fast-growing, aggressive form of NHL. - Nov 2, 2022"
"DLBCL is a fast-growing, aggressive form of NHL. DLBCL is fatal if left untreated, but with timely and appropriate treatment, approximately two-thirds of all people can be cured."
https://www.uptodate.com/contents/diffu ... -basics#H1
Targeting Non-Hodgkin Lymphoma is an $8B+ Global Market Potential
https://www.businesswire.com/news/home/ ... arkets.com
With Dr. Rizo's experience and background with lymphomas at Janssen and getting involved with MD Anderson Cancer Center, one would think the book wasn't closed on this story just yet? -Kmall
"telomerase may be a therapeutic target for ABC-type DLBCL (diffuse large B-cell lymphoma); the novel telomerase inhibitor Imetelstat may present one of the potential treatment options."
https://ashpublications.org/blood/artic ... chresult=1
I know that "imetelstat single-agent activity on cell viability was limited in PTCL (peripheral T-cell lymphomas) cell lines"..... however, from a company/business perspective it makes sense to pursue type DLBCL even further.
"PTCL is classified as a subtype of non-Hodgkin’s lymphoma (NHL)."
https://lymphoma.org/understanding-lymp ... /nhl/ptcl/
PTCL - "is rare in the United States, accounting for less than 1.5 percent of all NHLs. Extranodal, nasal NK/T-cell lymphoma is more commonly found in Asia and Latin America and is associated with the Epstein-Barr virus (EBV)."
https://www.google.com/url?sa=t&source= ... jOy6ZRsanh
"Although there are more than 60 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas. In the United States, DLBCL affects about 7 out of 100,000 people each year. DLBCL is a fast-growing, aggressive form of NHL. - Nov 2, 2022"
"DLBCL is a fast-growing, aggressive form of NHL. DLBCL is fatal if left untreated, but with timely and appropriate treatment, approximately two-thirds of all people can be cured."
https://www.uptodate.com/contents/diffu ... -basics#H1
Targeting Non-Hodgkin Lymphoma is an $8B+ Global Market Potential
https://www.businesswire.com/news/home/ ... arkets.com
With Dr. Rizo's experience and background with lymphomas at Janssen and getting involved with MD Anderson Cancer Center, one would think the book wasn't closed on this story just yet? -Kmall
Re: If we like what we see tomorrow…
Congrats, guys and gals. What a ride. Cheers.
Re: If we like what we see tomorrow…
How long are we holding? I'm in it to win it. Kmall? BP?
-
biopearl123
- Posts: 1670
- Joined: Fri Jul 20, 2018 5:13 pm
Re: If we like what we see tomorrow…
KT, hard to know the future is… probably until acquisition